Alaunos Therapeutics (TCRT)
(Delayed Data from NSDQ)
$2.63 USD
-0.11 (-4.01%)
Updated Oct 4, 2024 03:53 PM ET
After-Market: $2.59 -0.04 (-1.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
TCRT 2.63 -0.11(-4.01%)
Will TCRT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TCRT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TCRT
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study
TCRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Alaunos (TCRT) Stock Sinks As Market Gains: What You Should Know
Other News for TCRT
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024
Ziopharm: Q2 Earnings Snapshot
Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ZIOPHARM Oncology trading halted, news pending